Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Locally Recurrent or Metastatic Breast Cancer

NCT00600340 is registered in ClinicalTrials.gov with Central European Cooperative Oncology Group as lead sponsor.

NCT NCT00600340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Central European Cooperative Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
December 31, 2014
Enrollment
564 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer